 Christopher Ford
Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 22 | 2025 | 303 | 6.330 |
Why?
| | Corpus Striatum | 13 | 2025 | 167 | 4.820 |
Why?
| | Receptors, Dopamine D2 | 13 | 2025 | 97 | 4.530 |
Why?
| | Synaptic Transmission | 13 | 2025 | 289 | 2.880 |
Why?
| | Cholinergic Neurons | 4 | 2019 | 17 | 2.260 |
Why?
| | Neurons | 21 | 2025 | 1590 | 2.180 |
Why?
| | Inhibitory Postsynaptic Potentials | 9 | 2016 | 45 | 2.050 |
Why?
| | Nucleus Accumbens | 6 | 2021 | 138 | 1.910 |
Why?
| | Dopaminergic Neurons | 8 | 2025 | 69 | 1.620 |
Why?
| | Ventral Tegmental Area | 9 | 2025 | 58 | 1.500 |
Why?
| | Substantia Nigra | 7 | 2023 | 57 | 1.450 |
Why?
| | Receptor, Muscarinic M4 | 2 | 2024 | 3 | 1.440 |
Why?
| | Synapses | 7 | 2024 | 427 | 1.370 |
Why?
| | Locus Coeruleus | 4 | 2025 | 23 | 1.290 |
Why?
| | Interneurons | 6 | 2021 | 122 | 1.220 |
Why?
| | Glutamic Acid | 5 | 2025 | 246 | 1.170 |
Why?
| | Ganglia, Sympathetic | 4 | 2008 | 14 | 0.930 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2024 | 12 | 0.920 |
Why?
| | Levodopa | 1 | 2024 | 30 | 0.910 |
Why?
| | Mice | 33 | 2025 | 17787 | 0.870 |
Why?
| | Dynorphins | 2 | 2022 | 9 | 0.860 |
Why?
| | Signal Transduction | 9 | 2025 | 5079 | 0.850 |
Why?
| | Parkinsonian Disorders | 2 | 2021 | 35 | 0.820 |
Why?
| | Receptors, Dopamine D1 | 2 | 2021 | 34 | 0.820 |
Why?
| | Animals | 43 | 2025 | 36940 | 0.800 |
Why?
| | Neostriatum | 2 | 2021 | 33 | 0.800 |
Why?
| | Acetylcholine | 5 | 2024 | 185 | 0.800 |
Why?
| | Cholinergic Agents | 2 | 2019 | 18 | 0.790 |
Why?
| | Neurotransmitter Agents | 5 | 2023 | 81 | 0.740 |
Why?
| | Neural Inhibition | 5 | 2009 | 169 | 0.740 |
Why?
| | Thalamus | 2 | 2021 | 107 | 0.740 |
Why?
| | Dendrites | 4 | 2025 | 105 | 0.730 |
Why?
| | Parkinson Disease | 2 | 2024 | 493 | 0.710 |
Why?
| | Parasympathetic Nervous System | 1 | 2021 | 27 | 0.700 |
Why?
| | Motor Disorders | 1 | 2021 | 15 | 0.700 |
Why?
| | Norepinephrine | 4 | 2025 | 204 | 0.680 |
Why?
| | Cocaine-Related Disorders | 1 | 2021 | 113 | 0.670 |
Why?
| | Action Potentials | 5 | 2019 | 493 | 0.650 |
Why?
| | Cocaine | 2 | 2021 | 166 | 0.640 |
Why?
| | Optogenetics | 5 | 2024 | 108 | 0.620 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2019 | 219 | 0.620 |
Why?
| | Mesencephalon | 5 | 2023 | 66 | 0.620 |
Why?
| | Calcium Channels | 4 | 2019 | 159 | 0.610 |
Why?
| | Mice, Inbred C57BL | 15 | 2025 | 5757 | 0.590 |
Why?
| | Patch-Clamp Techniques | 11 | 2012 | 286 | 0.570 |
Why?
| | Receptors, Opioid | 1 | 2016 | 25 | 0.520 |
Why?
| | Cerebral Cortex | 1 | 2019 | 433 | 0.490 |
Why?
| | Neuronal Plasticity | 4 | 2024 | 290 | 0.490 |
Why?
| | Receptor, Serotonin, 5-HT1A | 1 | 2015 | 38 | 0.490 |
Why?
| | Serotonergic Neurons | 1 | 2015 | 29 | 0.480 |
Why?
| | Nerve Growth Factors | 2 | 2008 | 79 | 0.480 |
Why?
| | Raphe Nuclei | 1 | 2015 | 110 | 0.460 |
Why?
| | Gonadotropin-Releasing Hormone | 3 | 2008 | 212 | 0.450 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2014 | 18 | 0.440 |
Why?
| | Receptors, Nicotinic | 1 | 2016 | 334 | 0.430 |
Why?
| | Phosphatidylinositol 4,5-Diphosphate | 2 | 2004 | 32 | 0.430 |
Why?
| | Potassium Channels | 3 | 2010 | 151 | 0.430 |
Why?
| | Axons | 3 | 2023 | 198 | 0.410 |
Why?
| | Electric Stimulation | 6 | 2012 | 264 | 0.390 |
Why?
| | Corticotropin-Releasing Hormone | 3 | 2022 | 68 | 0.380 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2025 | 198 | 0.380 |
Why?
| | Synaptic Vesicles | 2 | 2023 | 44 | 0.360 |
Why?
| | Male | 27 | 2025 | 67762 | 0.360 |
Why?
| | Mice, Transgenic | 4 | 2025 | 2167 | 0.340 |
Why?
| | In Vitro Techniques | 7 | 2012 | 1092 | 0.330 |
Why?
| | Mice, Inbred DBA | 5 | 2015 | 200 | 0.310 |
Why?
| | Egtazic Acid | 2 | 2009 | 40 | 0.310 |
Why?
| | Time Factors | 8 | 2014 | 6828 | 0.310 |
Why?
| | Receptors, AMPA | 2 | 2021 | 141 | 0.300 |
Why?
| | Sodium Channels | 2 | 2010 | 65 | 0.300 |
Why?
| | G Protein-Coupled Inwardly-Rectifying Potassium Channels | 3 | 2016 | 10 | 0.290 |
Why?
| | Sucrose | 2 | 2025 | 110 | 0.280 |
Why?
| | Organ Culture Techniques | 3 | 2014 | 156 | 0.280 |
Why?
| | Electrochemistry | 4 | 2012 | 78 | 0.280 |
Why?
| | Adrenergic Neurons | 2 | 2018 | 6 | 0.270 |
Why?
| | Receptors, Opioid, kappa | 1 | 2006 | 10 | 0.270 |
Why?
| | Rana catesbeiana | 5 | 2008 | 12 | 0.250 |
Why?
| | Limbic System | 1 | 2006 | 47 | 0.250 |
Why?
| | Narcotics | 1 | 2006 | 52 | 0.240 |
Why?
| | Vesicular Glutamate Transport Proteins | 1 | 2025 | 2 | 0.240 |
Why?
| | Septal Nuclei | 1 | 2025 | 23 | 0.230 |
Why?
| | Prefrontal Cortex | 1 | 2008 | 301 | 0.230 |
Why?
| | GABA Antagonists | 3 | 2010 | 35 | 0.230 |
Why?
| | Exploratory Behavior | 1 | 2025 | 92 | 0.230 |
Why?
| | GABAergic Neurons | 1 | 2025 | 35 | 0.230 |
Why?
| | Serotonin | 3 | 2015 | 323 | 0.230 |
Why?
| | Arousal | 1 | 2025 | 155 | 0.220 |
Why?
| | Neural Pathways | 3 | 2012 | 295 | 0.220 |
Why?
| | Female | 19 | 2025 | 73304 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 2057 | 0.220 |
Why?
| | Protein Biosynthesis | 2 | 2024 | 433 | 0.210 |
Why?
| | Rats, Sprague-Dawley | 4 | 2025 | 2486 | 0.200 |
Why?
| | Reward | 1 | 2025 | 244 | 0.200 |
Why?
| | HEK293 Cells | 3 | 2024 | 730 | 0.200 |
Why?
| | Membrane Potentials | 4 | 2011 | 284 | 0.200 |
Why?
| | Calcium | 5 | 2012 | 1199 | 0.190 |
Why?
| | Movement Disorders | 1 | 2022 | 58 | 0.190 |
Why?
| | Rats | 5 | 2025 | 5647 | 0.190 |
Why?
| | Basal Ganglia | 1 | 2022 | 56 | 0.190 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 143 | 0.190 |
Why?
| | Biophysics | 3 | 2011 | 71 | 0.180 |
Why?
| | Heroin | 1 | 2021 | 31 | 0.180 |
Why?
| | Extinction, Psychological | 1 | 2021 | 86 | 0.170 |
Why?
| | Phosphinic Acids | 2 | 2010 | 9 | 0.170 |
Why?
| | Behavior, Animal | 2 | 2021 | 501 | 0.170 |
Why?
| | Carrier Proteins | 1 | 2024 | 771 | 0.160 |
Why?
| | Analysis of Variance | 3 | 2012 | 1316 | 0.160 |
Why?
| | Adaptor Protein Complex 3 | 1 | 2019 | 3 | 0.160 |
Why?
| | Propanolamines | 2 | 2010 | 96 | 0.160 |
Why?
| | Exocytosis | 1 | 2019 | 89 | 0.150 |
Why?
| | Enzyme Inhibitors | 4 | 2008 | 840 | 0.150 |
Why?
| | GTP-Binding Protein gamma Subunits | 1 | 2018 | 5 | 0.150 |
Why?
| | GTP-Binding Protein beta Subunits | 1 | 2018 | 11 | 0.150 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2018 | 40 | 0.150 |
Why?
| | Botulinum Toxins | 1 | 2019 | 41 | 0.150 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2018 | 16 | 0.150 |
Why?
| | Single-Domain Antibodies | 1 | 2018 | 15 | 0.140 |
Why?
| | Membrane Proteins | 1 | 2024 | 1164 | 0.140 |
Why?
| | Oxidopamine | 1 | 2017 | 17 | 0.140 |
Why?
| | MicroRNAs | 1 | 2024 | 692 | 0.140 |
Why?
| | Chelating Agents | 2 | 2009 | 75 | 0.130 |
Why?
| | Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2016 | 12 | 0.130 |
Why?
| | Ambenonium Chloride | 1 | 2016 | 1 | 0.130 |
Why?
| | Subthalamic Nucleus | 1 | 2017 | 72 | 0.130 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 1000 | 0.130 |
Why?
| | Cholinesterase Inhibitors | 1 | 2016 | 30 | 0.130 |
Why?
| | Neurotensin | 1 | 2015 | 14 | 0.120 |
Why?
| | Vesicular Inhibitory Amino Acid Transport Proteins | 2 | 2025 | 10 | 0.120 |
Why?
| | Cells, Cultured | 4 | 2019 | 4193 | 0.110 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4295 | 0.110 |
Why?
| | Stress, Psychological | 2 | 2015 | 1100 | 0.110 |
Why?
| | Drug Interactions | 2 | 2006 | 410 | 0.110 |
Why?
| | Ion Channel Gating | 2 | 2004 | 90 | 0.100 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2011 | 100 | 0.100 |
Why?
| | Mice, Knockout | 2 | 2018 | 3015 | 0.100 |
Why?
| | Sex Characteristics | 1 | 2018 | 762 | 0.100 |
Why?
| | Guinea Pigs | 1 | 2012 | 158 | 0.100 |
Why?
| | Methyl-CpG-Binding Protein 2 | 1 | 2011 | 21 | 0.090 |
Why?
| | Peptide Fragments | 1 | 2015 | 706 | 0.090 |
Why?
| | Species Specificity | 1 | 2012 | 585 | 0.090 |
Why?
| | Iontophoresis | 1 | 2010 | 13 | 0.080 |
Why?
| | Adenosine Triphosphate | 2 | 2003 | 491 | 0.080 |
Why?
| | Calcineurin | 2 | 2024 | 108 | 0.080 |
Why?
| | Picrotoxin | 1 | 2009 | 12 | 0.080 |
Why?
| | Quinpirole | 1 | 2009 | 10 | 0.080 |
Why?
| | Dextrans | 1 | 2010 | 84 | 0.080 |
Why?
| | Dizocilpine Maleate | 1 | 2009 | 22 | 0.080 |
Why?
| | Rhodamines | 1 | 2009 | 20 | 0.080 |
Why?
| | Dopamine Agonists | 1 | 2009 | 39 | 0.080 |
Why?
| | Receptors, Dopamine | 2 | 2024 | 20 | 0.080 |
Why?
| | Quinoxalines | 1 | 2009 | 66 | 0.080 |
Why?
| | Calcium Channels, T-Type | 1 | 2010 | 96 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 431 | 0.070 |
Why?
| | Phorbol Esters | 1 | 2008 | 14 | 0.070 |
Why?
| | rap1 GTP-Binding Proteins | 1 | 2008 | 4 | 0.070 |
Why?
| | Anxiety | 1 | 2015 | 1035 | 0.070 |
Why?
| | Humans | 9 | 2024 | 137585 | 0.070 |
Why?
| | Receptors, Presynaptic | 1 | 2007 | 10 | 0.070 |
Why?
| | Electric Conductivity | 2 | 2004 | 86 | 0.070 |
Why?
| | Sulpiride | 2 | 2022 | 5 | 0.070 |
Why?
| | Synaptic Membranes | 1 | 2006 | 18 | 0.070 |
Why?
| | Indoles | 1 | 2010 | 412 | 0.070 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2007 | 124 | 0.070 |
Why?
| | Organic Chemicals | 1 | 2008 | 124 | 0.060 |
Why?
| | Temperature | 1 | 2009 | 679 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2008 | 313 | 0.060 |
Why?
| | Bicuculline | 1 | 2006 | 23 | 0.060 |
Why?
| | Serotonin Receptor Agonists | 1 | 2006 | 26 | 0.060 |
Why?
| | Microinjections | 1 | 2006 | 86 | 0.060 |
Why?
| | Biotin | 1 | 2006 | 28 | 0.060 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2006 | 72 | 0.060 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2006 | 141 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1738 | 0.060 |
Why?
| | Arcuate Nucleus of Hypothalamus | 1 | 2025 | 16 | 0.060 |
Why?
| | Paraventricular Hypothalamic Nucleus | 1 | 2025 | 32 | 0.060 |
Why?
| | Vesicular Glutamate Transport Protein 2 | 1 | 2025 | 15 | 0.060 |
Why?
| | Gene Expression Regulation | 3 | 2024 | 2607 | 0.060 |
Why?
| | Cell Count | 1 | 2006 | 324 | 0.060 |
Why?
| | Dialysis | 1 | 2004 | 20 | 0.060 |
Why?
| | Naloxone | 1 | 2006 | 122 | 0.060 |
Why?
| | Photometry | 1 | 2024 | 4 | 0.060 |
Why?
| | Avoidance Learning | 1 | 2025 | 76 | 0.060 |
Why?
| | Amygdala | 1 | 2006 | 191 | 0.060 |
Why?
| | Intracellular Space | 1 | 2004 | 68 | 0.060 |
Why?
| | Reaction Time | 1 | 2006 | 412 | 0.050 |
Why?
| | Allosteric Regulation | 1 | 2024 | 97 | 0.050 |
Why?
| | NFATC Transcription Factors | 1 | 2024 | 95 | 0.050 |
Why?
| | Narcotic Antagonists | 1 | 2006 | 181 | 0.050 |
Why?
| | Analgesics | 1 | 2006 | 206 | 0.050 |
Why?
| | Vesicular Monoamine Transport Proteins | 1 | 2023 | 7 | 0.050 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2003 | 8 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2024 | 2833 | 0.050 |
Why?
| | 1-Phosphatidylinositol 4-Kinase | 1 | 2003 | 3 | 0.050 |
Why?
| | Calcium Channels, N-Type | 1 | 2003 | 10 | 0.050 |
Why?
| | KCNQ3 Potassium Channel | 1 | 2003 | 3 | 0.050 |
Why?
| | Denervation | 1 | 2003 | 24 | 0.050 |
Why?
| | Receptors, LHRH | 1 | 2003 | 14 | 0.050 |
Why?
| | Muscarinic Agonists | 1 | 2003 | 16 | 0.050 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2003 | 10 | 0.050 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2003 | 47 | 0.050 |
Why?
| | Receptors, GABA-A | 1 | 2024 | 142 | 0.050 |
Why?
| | Recurrence | 2 | 2021 | 1060 | 0.050 |
Why?
| | Aluminum | 1 | 2003 | 42 | 0.050 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2003 | 50 | 0.050 |
Why?
| | Heparin | 1 | 2004 | 261 | 0.050 |
Why?
| | COS Cells | 1 | 2003 | 188 | 0.050 |
Why?
| | Androstadienes | 1 | 2003 | 107 | 0.050 |
Why?
| | Hyperkinesis | 1 | 2022 | 16 | 0.050 |
Why?
| | Histone Deacetylases | 1 | 2024 | 215 | 0.050 |
Why?
| | Long-Term Potentiation | 1 | 2024 | 198 | 0.050 |
Why?
| | Type C Phospholipases | 1 | 2002 | 74 | 0.050 |
Why?
| | Calcium Channels, L-Type | 1 | 2003 | 118 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 313 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2900 | 0.040 |
Why?
| | Sympathetic Nervous System | 1 | 2002 | 182 | 0.040 |
Why?
| | Antibodies | 1 | 2003 | 410 | 0.040 |
Why?
| | Self Administration | 1 | 2021 | 123 | 0.040 |
Why?
| | Dopamine Antagonists | 2 | 2011 | 27 | 0.040 |
Why?
| | Gait | 1 | 2022 | 296 | 0.040 |
Why?
| | Vesicle-Associated Membrane Protein 2 | 1 | 2019 | 14 | 0.040 |
Why?
| | Protein Binding | 2 | 2018 | 2224 | 0.040 |
Why?
| | SNARE Proteins | 1 | 2019 | 39 | 0.040 |
Why?
| | Electrophysiology | 2 | 2010 | 217 | 0.040 |
Why?
| | Transcriptome | 1 | 2025 | 971 | 0.040 |
Why?
| | Cryptochromes | 1 | 2019 | 25 | 0.040 |
Why?
| | Receptors, Prostaglandin E, EP3 Subtype | 1 | 2018 | 2 | 0.040 |
Why?
| | Norepinephrine Plasma Membrane Transport Proteins | 1 | 2018 | 6 | 0.040 |
Why?
| | Gene Expression | 1 | 2003 | 1502 | 0.040 |
Why?
| | Guanosine Triphosphate | 1 | 2018 | 91 | 0.040 |
Why?
| | Arabidopsis Proteins | 1 | 2019 | 75 | 0.040 |
Why?
| | Dimerization | 1 | 2018 | 199 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 243 | 0.030 |
Why?
| | Ribosomes | 1 | 2018 | 186 | 0.030 |
Why?
| | Light | 1 | 2019 | 381 | 0.030 |
Why?
| | Receptors, Neurotensin | 1 | 2015 | 11 | 0.030 |
Why?
| | Protein Kinase C | 2 | 2010 | 261 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1353 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 2019 | 306 | 0.030 |
Why?
| | Binding Sites | 1 | 2018 | 1303 | 0.030 |
Why?
| | Presynaptic Terminals | 1 | 2015 | 88 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2018 | 886 | 0.030 |
Why?
| | Radioligand Assay | 1 | 2011 | 48 | 0.020 |
Why?
| | Tritium | 1 | 2011 | 76 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2018 | 1457 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3958 | 0.020 |
Why?
| | Neural Conduction | 1 | 2011 | 86 | 0.020 |
Why?
| | Electrochemical Techniques | 1 | 2011 | 54 | 0.020 |
Why?
| | Cochlear Nucleus | 1 | 2010 | 5 | 0.020 |
Why?
| | Receptors, Dopamine D3 | 1 | 2010 | 4 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 2010 | 54 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2010 | 119 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 216 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3284 | 0.020 |
Why?
| | Receptors, GABA-B | 1 | 2009 | 11 | 0.020 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2009 | 29 | 0.020 |
Why?
| | Restraint, Physical | 1 | 2009 | 72 | 0.020 |
Why?
| | Colforsin | 1 | 2007 | 53 | 0.020 |
Why?
| | Central Nervous System Stimulants | 1 | 2009 | 161 | 0.020 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 59 | 0.020 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2009 | 179 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 2071 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3295 | 0.010 |
Why?
| | Phenanthridines | 1 | 2002 | 7 | 0.010 |
Why?
| | Benzophenanthridines | 1 | 2002 | 10 | 0.010 |
Why?
| | Thapsigargin | 1 | 2002 | 20 | 0.010 |
Why?
| | Estrenes | 1 | 2002 | 16 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 2002 | 21 | 0.010 |
Why?
| | Culture Techniques | 1 | 2002 | 81 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate Receptors | 1 | 2002 | 28 | 0.010 |
Why?
| | Pyrrolidinones | 1 | 2002 | 28 | 0.010 |
Why?
| | Alkaloids | 1 | 2002 | 30 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2002 | 84 | 0.010 |
Why?
| | ras Proteins | 1 | 2002 | 153 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 220 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 2009 | 1083 | 0.010 |
Why?
|
|
Ford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|